Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Breast cancer subtypes
Imaging features
PI3K pathway
PIK3CA protein expression
Triple negative breast cancer
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
22
05
2019
accepted:
01
07
2019
pubmed:
5
7
2019
medline:
9
8
2019
entrez:
5
7
2019
Statut:
ppublish
Résumé
Triple negative breast cancer (TNBC) harbors a heterogeneous group of carcinomas with poor prognosis and high genetic variability. As a potential aim for targeted therapy, genetic mutations leading to an activation of the phosphoinositide 3-kinase pathway in a catalytic subunit (PIK3CA) in breast cancer have been analyzed currently. Little is known about the clinical impact and prognostic or predictive value of this marker in TNBC subtypes. Samples from 119 TNBC cases were submitted to immunohistochemical PIK3CA protein expression analysis and scored semi-quantitatively as negative, weak (1 +), or strongly expressed (2 +). Expression scores were correlated to patient's characteristics, imaging features, and TNBC subtypes. TNBC subtypes were categorized into four subtypes: basal like, mesenchymal like, luminal androgen receptor (LAR), and immunomodulatory. We did not observe differences in clinical aspects and imaging features between TNBC with and without PIK3CA expression. PIK3CA expression was in general higher in the LAR subtype. The disease-free survival and overall survival were significantly better in TNBC with PIK3CA protein expression, independent of TNBC subtypes. Despite conflicting results in the literature, our study clearly shows a better outcome of PIK3CA-expressing TNBC, independent of TNBC subtypes. PIK3CA expression in TNBC is not associated with specific clinical or diagnostic features. Further molecular studies and meta-analysis are warranted to clarify the prognostic and predictive role of PIK3CA protein expression.
Sections du résumé
BACKGROUND
BACKGROUND
Triple negative breast cancer (TNBC) harbors a heterogeneous group of carcinomas with poor prognosis and high genetic variability. As a potential aim for targeted therapy, genetic mutations leading to an activation of the phosphoinositide 3-kinase pathway in a catalytic subunit (PIK3CA) in breast cancer have been analyzed currently. Little is known about the clinical impact and prognostic or predictive value of this marker in TNBC subtypes.
METHODS
METHODS
Samples from 119 TNBC cases were submitted to immunohistochemical PIK3CA protein expression analysis and scored semi-quantitatively as negative, weak (1 +), or strongly expressed (2 +). Expression scores were correlated to patient's characteristics, imaging features, and TNBC subtypes. TNBC subtypes were categorized into four subtypes: basal like, mesenchymal like, luminal androgen receptor (LAR), and immunomodulatory.
RESULTS
RESULTS
We did not observe differences in clinical aspects and imaging features between TNBC with and without PIK3CA expression. PIK3CA expression was in general higher in the LAR subtype. The disease-free survival and overall survival were significantly better in TNBC with PIK3CA protein expression, independent of TNBC subtypes.
CONCLUSION
CONCLUSIONS
Despite conflicting results in the literature, our study clearly shows a better outcome of PIK3CA-expressing TNBC, independent of TNBC subtypes. PIK3CA expression in TNBC is not associated with specific clinical or diagnostic features. Further molecular studies and meta-analysis are warranted to clarify the prognostic and predictive role of PIK3CA protein expression.
Identifiants
pubmed: 31270600
doi: 10.1007/s00432-019-02968-2
pii: 10.1007/s00432-019-02968-2
doi:
Substances chimiques
Biomarkers, Tumor
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2051-2059Références
Ann Oncol. 1999 Apr;10(4):413-9
pubmed: 10370783
Nat Rev Genet. 2006 Aug;7(8):606-19
pubmed: 16847462
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Breast J. 2008 Sep-Oct;14(5):456-63
pubmed: 18657139
Cancer Res. 2009 May 15;69(10):4116-24
pubmed: 19435916
Clin Cancer Res. 2009 Aug 15;15(16):5049-59
pubmed: 19671852
Int J Cancer. 2010 Mar 1;126(5):1121-31
pubmed: 19685490
Cancer Res. 2011 Jul 1;71(13):4344-51
pubmed: 21482677
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
J Clin Oncol. 2011 Nov 20;29(33):4452-61
pubmed: 22010023
Breast Cancer Res. 2012 Feb 13;14(1):R28
pubmed: 22330809
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
Breast Cancer Res Treat. 2012 Jul;134(1):333-43
pubmed: 22538770
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Clin Cancer Res. 2013 Dec 1;19(23):6380-8
pubmed: 24298068
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Oncologist. 2014 Jun;19(6):608-15
pubmed: 24794159
Breast Cancer Res. 2014 Aug 08;16(4):406
pubmed: 25103565
Cancer Biol Med. 2015 Jun;12(2):106-16
pubmed: 26175926
Neoplasia. 2016 Apr;18(4):253-63
pubmed: 27108388
Sci Transl Med. 2016 Dec 14;8(369):369ra175
pubmed: 27974663
Clin Cancer Res. 2017 Jul 15;23(14):3859-3870
pubmed: 28153863
Breast. 2018 Apr;38:30-38
pubmed: 29202330
Cell. 2018 May 3;173(4):879-893.e13
pubmed: 29681456
J Pathol. 2018 Jul;245(3):373-383
pubmed: 29708279
J Transl Med. 2018 May 8;16(1):118
pubmed: 29739401
Oncologist. 2018 Nov;23(11):1300-1309
pubmed: 30139837
J Breast Cancer. 2018 Dec;21(4):382-390
pubmed: 30607159
Breast. 2019 Apr;44:81-89
pubmed: 30690254
J Cancer Res Clin Oncol. 2019 May;145(5):1235-1242
pubmed: 30806788
Cancer Cell. 2019 Mar 18;35(3):428-440.e5
pubmed: 30853353
Oncol Lett. 2019 Mar;17(3):3581-3588
pubmed: 30867801